Endocrine Society GUIDELINES Bundle (free trial)

Obesity

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1140184

Contents of this Issue

Navigation

Page 6 of 11

Table 3. Drugs Associated with Weight Gain and Suggested Alternatives (continued) (Where evidence is mixed or reports are of a few cases, a "?" has been added.) Category Drug Class Weight Gain Alternatives – weight reducing in parentheses Cardiologic Agents Antihypertensives • α-Blocker? • β-Blocker? • ACE inhibitors? • Calcium channel blockers? • Angiotensin-2 receptor antagonists Infectious Disease Agents Antiretroviral therapy • Protease inhibitors • None General Steroid hormones • Corticosteroids • Progestational steroids • NSAIDs Antihistamines/ anticholinergics • Diphenhydramine? • Doxepin? • Cyproheptadine? • Decongestants • Steroid inhalers Table 4. Advantages and Disadvantages Associated with Weight Loss Medications Drug Advantages Disadvantages Phentermine • Inexpensive ($) a • Side effect profile • No long-term data b Topiramate/phentermine • Long-term data b • Teratogen Lorcaserin • Side effect profile • Long-term data b • Less robust weight loss and not recommended for patients on SSRIs Orlistat, prescription • Nonsystemic • Long-term data b • Tolerability profile Orlistat, over-the-counter • Safety profile • Over-the-counter • Side effect profile Naltrexone/bupropion • Effect on food craving • Long-term data b • Side effect profile • Mid-level price range ($$) a Liraglutide • Side effect profile • Long-term data b • Injectable a Discounts and promotional coupons may be available. Co-pays may vary. b Long-term = 1–2 years.

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Obesity